Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Michael Kishko"'
Autor:
Catherine Berry, Vincent Pavot, Natalie G. Anosova, Michael Kishko, Lu Li, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Sheila Cummings, Dinesh S. Bangari, Swagata Kar, Caroline Atyeo, Yixiang Deng, Galit Alter, Cindy Gutzeit, Marguerite Koutsoukos, Roman M. Chicz, Valerie Lecouturier
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-16 (2023)
Abstract Background Since the beginning of the COVID-19 pandemic, several variants of concern (VOC) have emerged for which there is evidence of an increase in transmissibility, more severe disease, and/or reduced vaccine effectiveness. Effective COVI
Externí odkaz:
https://doaj.org/article/7ddec5d298994b9fb951ab9ada5f2108
Autor:
Judith Alamares-Sapuay, Michael Kishko, Charles Lai, Mark Parrington, Simon Delagrave, Richard Herbert, Ashley Castens, Joanna Swerczek, Cindy Luongo, Lijuan Yang, Peter L. Collins, Ursula J. Buchholz, Linong Zhang
Publikováno v:
PLoS ONE, Vol 19, Iss 4 (2024)
Externí odkaz:
https://doaj.org/article/cdf69bc8bef347239be7ac03a8140d99
Autor:
Vincent Pavot, Catherine Berry, Michael Kishko, Natalie G. Anosova, Lu Li, Tim Tibbitts, Dean Huang, Alice Raillard, Sylviane Gautheron, Cindy Gutzeit, Marguerite Koutsoukos, Roman M. Chicz, Valerie Lecouturier
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
Waning protective efficacy of mRNA-based booster vaccinations has been observed against newly emerging SARS-CoV-2 variants of concern. In this work, Pavot et al. formulate a monovalent Beta vaccine and demonstrate durable cross-neutralising antibody
Externí odkaz:
https://doaj.org/article/82bb567df3234c4eb6b85d8731df0e1a
Autor:
Jennifer N. Rainho-Tomko, Vincent Pavot, Michael Kishko, Kurt Swanson, Darin Edwards, Heesik Yoon, Lilibeth Lanza, Judith Alamares-Sapuay, Robert Osei-Bonsu, Sophia T. Mundle, Dave A. Murison, Scott Gallichan, Simon Delagrave, Chih-Jen Wei, Linong Zhang, Gary J. Nabel
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-9 (2022)
Abstract Respiratory syncytial virus (RSV) G glycoprotein has recently reemerged as a vaccine antigen due to its ability to elicit potent neutralizing antibodies and ameliorate disease in animal models. Here we designed three constructs to display th
Externí odkaz:
https://doaj.org/article/ebfed4caf551425eb43d4a04f2b4e65f
Autor:
Vincent Pavot, Catherine Berry, Michael Kishko, Natalie G. Anosova, Dean Huang, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Cindy Gutzeit, Marguerite Koutsoukos, Roman M. Chicz, Valerie Lecouturier
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Emerging SARS-CoV-2 variants of concern (VOCs) raise questions on vaccine effectiveness. Here, the authors show that an adjuvanted protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization of VOC, including omicron, in non-human p
Externí odkaz:
https://doaj.org/article/c8ccb39de4d2489d998cfdfb67a40d60
Autor:
Kirill V. Kalnin, Timothy Plitnik, Michael Kishko, Jinrong Zhang, Donghui Zhang, Adrien Beauvais, Natalie G. Anosova, Tim Tibbitts, Josh DiNapoli, Gregory Ulinski, Peter Piepenhagen, Sheila M. Cummings, Dinesh S. Bangari, Susan Ryan, Po-Wei D. Huang, James Huleatt, Deanne Vincent, Katherine Fries, Shrirang Karve, Rebecca Goldman, Hardip Gopani, Anusha Dias, Khang Tran, Minnie Zacharia, Xiaobo Gu, Lianne Boeglin, Jonathan Abysalh, Jorel Vargas, Angela Beaulieu, Monic Shah, Travis Jeannotte, Kimberly Gillis, Sudha Chivukula, Ron Swearingen, Victoria Landolfi, Tong-Ming Fu, Frank DeRosa, Danilo Casimiro
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
Abstract Emergency use authorization of COVID vaccines has brought hope to mitigate pandemic of coronavirus disease 2019 (COVID-19). However, there remains a need for additional effective vaccines to meet the global demand and address the potential n
Externí odkaz:
https://doaj.org/article/9fae835e0be047258ae7c50814033e8c
Autor:
Rachel Groppo, Joshua DiNapoli, Kwang Il Jeong, Michael Kishko, Nicholas Jackson, Harold Kleanthous, Simon Delagrave, Linong Zhang, Mark Parrington
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0199452 (2018)
A safe and effective vaccine against RSV remains an important unmet public health need. Intranasally (IN) delivered live-attenuated vaccines represent the most extensively studied approach for immunization of RSV-naïve infants and children, however,
Externí odkaz:
https://doaj.org/article/c509bc1f44d047088567bdb72d101f19
Autor:
Kwang-Il Jeong, Peter A Piepenhagen, Michael Kishko, Joshua M DiNapoli, Rachel P Groppo, Linong Zhang, Jeffrey Almond, Harry Kleanthous, Simon Delagrave, Mark Parrington
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0130517 (2015)
Respiratory syncytial virus (RSV) is the principal cause of bronchiolitis in infants and a significant healthcare problem. The RSV Glycoprotein (G) mediates attachment of the virus to the cell membrane, which facilitates interaction of the RSV Fusion
Externí odkaz:
https://doaj.org/article/dbc15e9381a84df4af70827d30767b46
Autor:
Vincent Pavot, Catherine Berry, Michael Kishko, Natalie Anosova, Lu Li, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Cindy Gutzeit, Marguerite Koutsoukos, Roman Chicz, Valerie Lecouturier
Rapid spread of the SARS-CoV-2 Omicron subvariants despite the implementation of booster vaccination has raised questions about the durability of protection conferred by current vaccines. Vaccines that can induce broader and more durable immune respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1df1f5123c090593527357733f928058
https://doi.org/10.21203/rs.3.rs-2372287/v1
https://doi.org/10.21203/rs.3.rs-2372287/v1
Autor:
Catherine Berry, Vincent Pavot, Natalie Anosova, Michael Kishko, Dean Huang, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Sheila Cummings, Dinesh Bangari, Swagata Kar, Caroline Atyeo, Yixiang Deng, Galit Alter, Cindy Gutzeit, Marguerite Koutsoukos, Roman Chicz, Valerie Lecouturier
Background Since the beginning of the COVID-19 pandemic, several variants of concern (VOC) have emerged for which there is evidence of an increase in transmissibility, more severe disease, and/or reduced vaccine effectiveness. Effective COVID-19 vacc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16e9a2ccc11a8cddb29e530d7503f5ad
https://doi.org/10.21203/rs.3.rs-1928234/v1
https://doi.org/10.21203/rs.3.rs-1928234/v1